Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tedopi (OSE Immunotherapeutics)
- Development stage
- Unknown
- Lead developer
- OSE Immunotherapeutics
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Tedopi (OSE2101) is a neo-epitope-based cancer vaccine designed to stimulate a specific cytotoxic T-lymphocyte response against tumor cells. It consists of 10 optimized neo-epitopes selected from five tumor-associated antigens: carcinoembryonic antigen (CEA), human epidermal growth factor receptor 2 (HER2/neu), tumor protein P53 (P53), melanoma-associated antigen 2 (MAGE-2), and melanoma-associated antigen 3 (MAGE-3). These antigens are frequently overexpressed in various solid tumors. The vaccine is specifically restricted to HLA-A2 positive patients, as the epitopes are designed to be presented by this specific human leukocyte antigen. Tedopi is being developed by OSE Immunotherapeutics and is being evaluated as a maintenance therapy in several indications, including non-small cell lung cancer (NSCLC) and ovarian cancer, often in combination with immune checkpoint inhibitors such as pembrolizumab.
- Brand names
- Tedopi
- Other names
- Neo-epitope Based Vaccine OSE2101
02
Targets
MAGEA3 (Melanoma-associated antigen 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MAGEA2 (Melanoma-associated antigen 2)TP53 (Cellular Tumor Antigen p53 R175H)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on Tedopi (OSE Immunotherapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tedopi (OSE Immunotherapeutics).